Skip to main content
. 2021 Sep 20;11:18605. doi: 10.1038/s41598-021-98169-4

Table 2.

Comparisons of incidence densities and hazard ratios of dyspepsia in exposed and control cohorts.

Control Apnea subgroup Crude HR
(95% CI)
Adjusted HR Non-apnea subgroup Crude HR (95% CI) Adjusted HR
Case Rate# Case Rate# (95% CI) Case Rate# (95% CI)
All 5919 6.73 175 18.9 2.80 (2.41,3.26) 3.31 (2.82, 3.89) 8532 21.0 3.08 (2.98,9.18) 3.98 (3.83,4.14)
Age
 ≤ 34 589 4.04 24 14.2 3.50 (2.33, 5.26) 3.72 (2.38, 5.80) 1201 17.3 4.24 (3.84, 4.68) 5.35 (4.76, 6.02)
35–49 1560 5.08 62 16.7 3.25 (2.52, 4.19) 3.27 (2.46, 4.34) 2638 19.1 3.71 (3.48, 3.95) 4.82 (4.47, 5.20)
50–64 1891 7.54 47 18.6 2.43 (1.82,3.25) 2.45 (1.80,3.33) 2375 21.0 2.74 (2.58,2.91) 3.68 (3.42,3.96)
 > 64 1879 10.7 42 32.3 3.04 (2.24,4.13) 4.01 (2.90,5.54) 2318 27.1 2.52 (2.37,2.68) 3.36 (3.12,3.61)
Gender
Women 3889 6.89 81 23.3 3.35 (2.69,4.18) 3.77 (2.98,4.76) 5534 20.9 3.00 (2.88,3.13) 3.99 (3.80,4.19)
Men 2030 6.44 94 16.3 2.54 (2.06,3.12) 3.14 (2.51, 3.93) 2998 21.2 3.23 (3.05,3.41) 3.99 (3.73,4.27)
Comorbidity
None 2890 4.88 47 14.9 3.05 (2.29,4.07) 4.09 (3.04,5.50) 2353 15.8 3.23 (3.06,3.41) 4.52 (4.24,4.83)
Diabetes 311 9.65 18 32.0 3.37 (2.09, 5.42) 4.53 (2.67, 7.67) 610 23.5 2.48 (2.16, 2.84) 3.67 (3.14, 4.28)
Hypertension 1839 10.2 85 23.7 2.34 (1.88, 2.90) 3.59 (2.84, 4.54) 3535 23.9 2.34 (2.21, 2.48) 3.59 (3.37, 3.83)
Hyperlipidemia 895 10.5 52 21.8 2.08 (1.58, 2.76) 2.79 (2.05, 3.80) 2056 25.3 2.40 (2.22, 2.59) 3.77 (3.44, 4.11)
Anxiety 47 11.3 14 34.5 3.05 (1.68, 5.55) 7.19 (3.12, 16.6) 564 27.9 2.46 (1.83, 3.31) 4.15 (3.04, 5.65)
Depression 61 14.9 10 17.8 1.18 (0.60, 2.33) 1.72 (0.76, 3.90) 633 25.2 1.76 (1.35, 2.29) 2.73 (2.08, 3.61)
Peptic ulcer disease 828 14.1 40 23.2 1.67 (1.22, 2.30) 2.67 (1.89, 3.77) 2239 30.0 2.12 (1.96, 2.30) 3.35 (3.06, 3.67)
Stroke 159 11.8 6 25.9 2.44 (1.08, 5.51) 2.96 (1.24, 7.08) 269 23.3 2.96 (1.24, 7.08) 2.85 (2.28, 3.55)
Ischemic heart disease 843 12.7 46 22.9 1.85 (1.37, 2.49) 2.78 (2.02, 3.83) 2186 28.6 2.27 (2.09, 2.45) 3.50 (3.20, 3.82)
Obesity 24 9.21 3 15.2 1.63 (0.49, 5.41) 2.11 (0.42, 10.6) 48 17.5 1.88 (1.15, 3.06) 3.06 (1.70, 5.51)
Irritable bowel syndrome 132 18.0 8 35.1 2.01 (0.99, 4.11) 4.19 (1.72, 10.2) 511 38.1 2.10 (1.74, 2.54) 3.21 (2.60, 3.96)
Cholecystitis 9 12.2 0 0.00 30 32.0 2.65 (1.26, 2.57) 7.23 (2.62, 20.0)
Cholelithiasis and other disorders of biliary tract 103 15.6 9 60.9 3.76 (1.90, 7.44) 7.02 (2.82, 17.5) 223 29.0 1.87 (1.48, 2.36) 2.99 (2.26, 3.98)
Alcoholism 41 9.00 7 31.3 3.49 (1.57, 7.78) 3.27 (1.07, 9.94) 187 21.7 2.41 (1.72, 3.38) 4.29 (2.92, 6.30)
Heart failure 95 14.6 4 20.5 1.49 (0.55, 4.05) 2.35 (0.79, 6.96) 222 32.4 2.30 (1.81, 2.92) 3.53 (2.72, 4.58)
Atrial fibrillation 19 9.08 0 0.00 44 26.4 2.93 (1.71, 5.03) 3.83 (2.07, 7.10)
Chronic kidney disease 448 14.5 21 24.2 1.71 (1.11, 2.66) 2.85 (1.77, 4.59) 921 29.2 2.05 (1.83, 2.29) 3.14 (2.77, 3.57)
Chronic obstructive pulmonary diseases 372 12.7 21 19.9 1.63 (1.05, 2.53) 2.76 (1.71, 4.45) 1033 30.8 2.46 (2.18, 2.77) 3.91 (3.43, 4.46)
Asthma 217 13.4 12 18.0 1.37 (0.77, 2.45) 2.32 (1.24, 4.34) 605 29.8 2.24 (1.92, 2.62) 3.66 (3.08, 4.35)
Fatigue 109 2.16 7 7.02 3.35 (1.56, 7.20) 5.11 (2.14, 12.2) 280 5.46 2.56 (2.05, 3.20) 2.54 (1.92, 3.35)
Benzodiazepine
No 1357 5.62 3 6.01 1.09 (0.35, 3.38) 1.12 (0.36, 3.50) 279 32.5 5.66 (4.98, 6.44) 6.68 (5.83, 7.66)
Yes 4562 7.15 172 19.7 2.74 (2.35, 3.19) 3.43 (2.91, 4.04) 8253 20.8 2.87 (2.77, 2.97) 3.86 (3.70, 4.02)
Zolpidem
No 5561 7.03 89 25.0 3.52 (2.86, 4.34) 3.29 (2.66, 4.07) 4908 35.9 4.90 (4.72, 5.10) 4.00 (3.83, 4.17)
Yes 358 4.04 86 15.1 3.71 (2.94, 4.70) 3.58 (2.77, 4.62) 3624 13.5 3.33 (2.99, 3.71) 3.01 (2.69, 3.37)

Rate#, incidence rate, per 1,000 person-years; Crude HR*, relative hazard ratio, per 10,000 person-years; Adjusted HR:models including age, sex, comorbidities, and medications.

For all significance: p < 0.001.